SEFFIN Drug Patent Profile
✉ Email this page to a colleague
When do Seffin patents expire, and what generic alternatives are available?
Seffin is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in SEFFIN is cephalothin sodium. There are seven drug master file entries for this compound. Additional details are available on the cephalothin sodium profile page.
Summary for SEFFIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 72 |
Patent Applications: | 1,064 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SEFFIN at DailyMed |
US Patents and Regulatory Information for SEFFIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | SEFFIN | cephalothin sodium | INJECTABLE;INJECTION | 062435-001 | Nov 15, 1983 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxosmithkline | SEFFIN | cephalothin sodium | INJECTABLE;INJECTION | 062435-002 | Nov 15, 1983 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxosmithkline | SEFFIN | cephalothin sodium | INJECTABLE;INJECTION | 062435-003 | Nov 15, 1983 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |